PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants

Vaccine

Volumn 27, Issue 45, 2009, Pages 6276-6279

  Ichinohe, Takeshi ^a,b   Ainai, Akira ^a   Tashiro, Masato ^a   Sata, Tetsutaro ^a   Hasegawa, Hideki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; H5N1; Heterosubtypic immunity; Influenza virus; Intranasal vaccine

Indexed keywords

AMPLIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VACCINE NIBRG14; UNCLASSIFIED DRUG; VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; POLYINOSINIC POLYCYTIDYLIC ACID; POLYURIDYLIC ACID; RINTATOLIMOD; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HONG KONG; INDONESIA; INFECTION PREVENTION; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT PLANNING; VACCINATION; VIET NAM; VIRUS STRAIN; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; ORTHOMYXOVIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CROSS PROTECTION; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; POLY I-C; POLY U;

EID: 70349972479     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.074     Document Type: Article

References (14)

1. Tamura S., Tanimoto T., and Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 58 August (4) (2005) 195-207
2. Asahi Y., Yoshikawa T., Watanabe I., Iwasaki T., Hasegawa H., Sato Y., et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168 March (6) (2002) 2930-2938
3. Hasegawa H., Ichinohe T., Tamura S., and Kurata T. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. Expert Rev Vaccines 6 April (2) (2007) 193-201
4. Ichinohe T., Watanabe I., Ito S., Fujii H., Moriyama M., Tamura S., et al. Synthetic double-stranded RNA poly (I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79 March (5) (2005) 2910-2919
5. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 October (10) (2004) 987-995
6. Robinson R.A., DeVita V.T., Levy H.B., Baron S., Hubbard S.P., and Levine A.S. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J Natl Cancer Inst 57 September (3) (1976) 599-602
7. Suhadolnik R.J., Reichenbach N.L., Hitzges P., Adelson M.E., Peterson D.L., Cheney P., et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly (I)-poly (C12U) in chronic fatigue syndrome. In Vivo (Athens, Greece) 8 July-August (4) (1994) 599-604
8. Gao P., Watanabe S., Ito T., Goto H., Wells K., McGregor M., et al. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J Virol 73 April (4) (1999) 3184-3189
9. Nicolson C., Major D., Wood J.M., and Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 April (22) (2005) 2943-2952
10. Ichinohe T., Kawaguchi A., Tamura S., Takahashi H., Sawa H., Ninomiya A., et al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect/Institut Pasteur 9 Septembre (11) (2007) 1333-1340
11. Ichinohe T., Tamura S., Kawaguchi A., Ninomiya A., Imai M., Itamura S., et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 196 November (9) (2007) 1313-1320
12. Ichinohe T., Iwasaki A., and Hasegawa H. Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Rev Vaccines 7 November (9) (2008) 1435-1445
13. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mitchell W.M., Alexopoulou L., et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly (I:C12U), but not poly (I:C) differential recognition of synthetic dsRNA molecules. J Immunol 178 April (8) (2007) 5200-5208
14. Asahi-Ozaki Y., Itamura S., Ichinohe T., Strong P., Tamura S., Takahashi H., et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect/Institut Pasteur 8 October (12-13) (2006) 2706-2714